BioHaven
Biohaven begins a clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some cases can be fatal in COVID-19
Rankings by 
National Ranking
282nd
in United StatesRegional Ranking
316th
in North America and CaribbeanGlobal Ranking
772nd
worldwide